PAM
ANTX icon

Panagora Asset Management’s AN2 Therapeutics ANTX Stock Holding History

Panagora Asset Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17,219
Closed -$299K – 1427
2022
Q3 		$299K Buy
+17,219
New +$201K ﹤0.01% 1280

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Panagora Asset Management's ANTX Position: Q4 2022 in Review

Panagora Asset Management sold out of AN2 Therapeutics (ANTX) in Q4 2022, closing a stake of 17,219 shares — an estimated $299K sold.

Panagora Asset Management first reported a position in ANTX in Q3 2022 and held it in 1 quarter. The position peaked at $299K in Q3 2022. 36 funds tracked by Wall St. Rank hold ANTX as of Q4 2022.

  • Panagora Asset Management reported no remaining AN2 Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Panagora Asset Management sold 17,219 AN2 Therapeutics shares in Q4 2022, an estimated $299K.
  • Panagora Asset Management first reported a position in AN2 Therapeutics in Q3 2022 and held it in 1 quarter.
  • Panagora Asset Management's AN2 Therapeutics position peaked at $299K in Q3 2022.
  • 36 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q4 2022.

Based on Panagora Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.